Innovation Pharmaceuticals Inc (IPIX)

[CallMeCrazy]

Symbiomix and Brilacidin are both single-dose antibiotics but it appears Synbiomix's cost advantages may not be as bright as Brilacidin's, for reasons stated in the last paragraph of the Fiercebiotech article you provided.

[/

No matter how preferential it may be on the adherence side, selling a drug like this [Symbiomix] as a branded treatment against a long-established generic could run into a wall of opposition from payers, who appear increasingly willing to trade less convenient dosing for patients in return for lower prices.

b]

http://www.fiercebiotech.com/story/symbiomix-pops-out-stealth-mode-41m-and-looming-phiii/2015-05-05

Symbiomix -- Another Ex of a Single-Dose ABX and the related clinical/cost advantages

This is the first time I've heard of a branded drug coming to market in the U.S. years AFTER its' generic version.